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Introduction: Post allogeneic HSCT chimerism analysis of
bone marrow (BM) and peripheral blood (PB) has been used
to monitor engraftment and to detect early disease recur-
rence. Mixed chimerism is occasionally encountered early
after RIC HSCT. The sensitivity of PB chimerism to detect
mixed BM chimerism remains to be determined. Our aim is
to determine the sensitivity of PB chimerism studies in pre-
dicting BMmixed chimerism post RIC allogeneic HSCT and to
determine the clinical relevance of early detection.
Methods: We did a retrospective review of chimerism data
from PB and BM samples from patients undergoing RIC
allogeneic HSCT from matched related, matched unrelated
and haploidentical donors. Chimerism data was collected
every 3 months during the ﬁrst year post HSCT. Only samples
drawn up to 5 days apart were included in the analysis.
Results: We analyzed 200 pairs of BM and PB samples in 89
patients with median age of 58 years (range 22-77). Of these,
132 pairs demonstrated </¼ 1% recipient cells in both
specimens (Marrow -, Blood -, M-B-), 45 pairs demonstrated
>1% recipient cells in both specimens (M+B+), 4 pairs had a
BM sample which showed </¼ 1% recipient cells and a PB
sample which showed >1% recipient cells (M-B+) and 19
pairs had a BM which showed >1% recipient cells and a PB
sample which showed </¼ 1% recipient cells (M+B-). The
ability of PB specimens to detect mixed BM chimerism
showed: 70% sensitivity, 97% speciﬁcity, positive predictive
value of 92%, and negative predictive value of 87%. The 19
M+B- specimens were from 16 patients (characteristics in
Table 1). Of these 16 patients, 4 relapsed (two at the time of
M+B-, one 22 days post-M+B-, and one 45months post-M+B-
) and 6 ultimately died (4 of relapse, 1 of infection, 1 of graftTable 1
Demographics
All patients Patients with M+/B- % M+/B-
Total patients 89 16 18%
Female 42 8 19%
Male 47 8 17%
Diagnosis
AML 26 4 15%
NHL 18 2 11%
MM 11 2 18%
CLL 7 4 57%
ALL 6 2 33%
Aplastic anemia 5 0 0%
Other 16 2 13%
Transplant type
Matched unrelated 16 2 13%
Matched related 28 4 14%
Haploidentical 45 10 22%
Status
Alive 49 10 20%
Deceased 40 6 15%vs. host disease). M+B- seen early post transplant (median
D+30) was not associated with relapse, while later detection
was associated with relapse (median D+137). The patients in
the M+/B- group who relapsed had acute leukemia (3/4) and
multiple myeloma (1/4).
Conclusions: PB chimerism had a high speciﬁcity; yet, it was
insufﬁciently sensitive (70%) to detect mixed BM chimerism
in patients undergoing RIC allogeneic HSCT. Though numbers
are small, peripheral blood samples best predict marrow
chimerism in patients with aplastic anemia rather than in
malignancies originating in the BM (leukemias and mye-
loma). Continued bone marrow sampling is thus required,
with the possible exception of patients transplanted for
aplastic anemia or malignancies not originating in the BM.360
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Low Dose Thymoglobulin Result in Improved Outcomes after
Allogeneic Unrelated Hematopoietic Stem Cell Trans-
plantation (HCT) for Patients with Acute Myeloid Leukemia/
Myelodysplastic Syndrome Conditioned with Intravenous
Busulfan and Fludarabine.
Intravenous Busulfan/Fludarabine (Bu/Flu) based condition-
ing regimens have resulted in lower treatment related mor-
tality (TRM) after allogeneic HCT in both reduced and full
intensity dosing in AML/MDS . The addition of thymoglobulin
to such regimens to minimize the risk of graft versus host
disease after unrelated donor (MUD) HCT has been linked to
the increased concerns of relapse risk.
Method: In order to study the impact of addition of low dose
thymoglobulin to Bu/Flu regimens in MUD recipients, the
medical records of 38 consecutive AML/MDS patients who
underwent MUD HCT with BU/Flu and low dose thymoglo-
bulin were retrospectively reviewed. All the patients
received single daily dose of iv Bu 3.2 mg/kg for 2 days (RIC,
Bu2-Flu) or 4 days (FIC, Bu4-Flu) based on age, older or
younger than 65 respectively. Fludarabine was given as a
single daily dose of 40 mg/Kg for 4 days. Graft versus host
